{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:46Z","timestamp":1786984306764,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010872","name":"King's College Hospital NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010872","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.amjsurg.2026.116856","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:47:13Z","timestamp":1770252433000},"page":"116856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Polycystic liver disease: Evidence-based management and critical gaps in surgical decision-making"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9600-7053","authenticated-orcid":false,"given":"Evangelia","family":"Florou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Prachalias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthi","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"35","key":"10.1016\/j.amjsurg.2026.116856_bib1","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.3748\/wjg.v19.i35.5775","article-title":"Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases","volume":"19","author":"Abu-Wasel","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pathol-042320-121247","article-title":"Polycystic liver disease: advances in understanding and treatment","volume":"17","author":"Masyuk","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.amjsurg.2026.116856_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","article-title":"Clinical management of polycystic liver disease","volume":"68","author":"van Aerts","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.116856_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.surg.2020.02.014","article-title":"Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease","volume":"168","author":"Bernts","year":"2020","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.116856_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SLA.0b013e3181ad83dc","article-title":"Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation","volume":"250","author":"Schnelldorfer","year":"2009","journal-title":"Ann Surg"},{"issue":"38","key":"10.1016\/j.amjsurg.2026.116856_bib7","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.3748\/wjg.v13.i38.5052","article-title":"Surgical management of polycystic liver disease","volume":"13","author":"Russell","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib8","author":"Duijzer","year":"2025","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.amjsurg.2026.116856_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101670","article-title":"Partial major hepatectomy with cyst fenestration for PLD: indications and outcomes","volume":"45","author":"Boillot","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"10.1016\/j.amjsurg.2026.116856_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.amjsurg.2026.116856_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.05.039","article-title":"Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease","volume":"13","author":"Temmerman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.116856_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.amjsurg.2026.116856_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4254\/wjh.v12.i3.72","article-title":"Polycystic liver disease: classification, diagnosis, treatment process, and clinical management","volume":"12","author":"Zhang","year":"2020","journal-title":"World J Hepatol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib35","first-page":"1159","article-title":"Clinical practice guidelines for cystic liver disease","volume":"77","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.amjsurg.2026.116856_bib14","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1053\/j.gastro.2004.08.006","article-title":"The cholangiopathies: disorders of biliary epithelia","volume":"127","author":"Lazaridis","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.amjsurg.2026.116856_bib15","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.116856_bib16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.amjsurg.2026.116856_bib17","first-page":"1273","article-title":"Long-term outcome of patients with polycystic liver disease treated with octreotide LAR: an open-label extension study","volume":"32","author":"Hogan","year":"2012","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.116856_bib18","first-page":"868","article-title":"The clinical use of somatostatin analogues in oncology","volume":"51","author":"Lamberts","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.amjsurg.2026.116856_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.amjsurg.2026.116856_bib20a","first-page":"1803","article-title":"Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume","volume":"34","author":"Wijnands","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.amjsurg.2026.116856_bib20b","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal-dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjsurg.2026.116856_bib22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney\/liver volume in ADPKD: randomized controlled trial","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.116856_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.116856_bib24","first-page":"46","article-title":"Ursodeoxycholic acid in polycystic liver disease: a randomized controlled trial","volume":"65","author":"D'Agnolo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib25","first-page":"142","article-title":"Estrogen modulation and rationale for anti-estrogen therapy in PLD (AGAINST-PLD framework)","volume":"22","author":"Aapkes","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"31","key":"10.1016\/j.amjsurg.2026.116856_bib26","article-title":"Tamoxifen for the treatment of polycystic liver disease: a case report","volume":"100","author":"Aapkes","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.amjsurg.2026.116856_bib27","first-page":"430","article-title":"Tolvaptan reduces liver cyst volume in polycystic liver disease: a case report","volume":"12","author":"Takenaka","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjsurg.2026.116856_bib28","first-page":"1107","article-title":"Effects of tolvaptan on liver volume in polycystic liver disease: observational report","volume":"61","author":"Mizuno","year":"2022","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.116856_bib29","first-page":"63","article-title":"Pharmacologic management of PLD: limitations of tolvaptan","volume":"3","author":"Ackley","year":"2023","journal-title":"Explor Dig Dis"},{"issue":"11","key":"10.1016\/j.amjsurg.2026.116856_bib30","article-title":"Hepatic safety of tolvaptan in ADPKD: updated data","volume":"17","author":"Jaeger","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjsurg.2026.116856_bib31","first-page":"1041","article-title":"Hepatic artery embolization for symptomatic polycystic liver disease","volume":"40","author":"Hoshino","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib32","first-page":"72","article-title":"Selective hepatic artery embolization in PLD: clinical outcomes","volume":"12","author":"Zhang","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjsurg.2026.116856_bib33","first-page":"1471","article-title":"Selective hepatic artery embolization reduces liver volume in polycystic liver disease","volume":"37","author":"Versteeg","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.amjsurg.2026.116856_bib34","first-page":"5312","article-title":"Partial liver transarterial embolization for symptomatic hepatomegaly in PLD: Multicentre outcomes","volume":"10","author":"Coussy","year":"2021","journal-title":"J Clin Med"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961026000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961026000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:31:23Z","timestamp":1772818283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961026000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0002961026000395"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.116856","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycystic liver disease: Evidence-based management and critical gaps in surgical decision-making","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.116856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116856"}}